Kamada (KMDA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$191.8M

Revenue (quarter)

$54.9M

Revenue growth (year over year)

+22.72%

Gross profit (trailing twelve months)

$78.3M

Gross margin

40.82%

Net income (trailing twelve months)

$22.3M

Net income (quarter)

$9.3M

Net income growth (year over year)

+25.57%

Net margin

11.60%

Return on equity

8.40%

EPS (trailing twelve months)

$0.38

Book value per share

$4.67

P/E (trailing twelve months)

19.71

Price to book

1.63

Debt to assets

29.65%

Payout ratio

56.94%

Dividend yield

5.52%

Company profile

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

• Is Kamada (KMDA) profitable?

  Yes. Kamada earned $22.3M in net income over the trailing twelve months, a net margin of 11.60%.

• How much revenue does Kamada (KMDA) make?

  Kamada generated $191.8M in revenue over the trailing twelve months, up 22.72% year over year.

• What is KMDA's P/E ratio?

  Kamada trades at 19.7 times trailing twelve-month earnings, on an EPS of $0.38.

• How do I buy stock in Kamada (KMDA)?

  KMDA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.